Surgalign to pay $2M to settle accounting fraud charges

Accounting fraud

A medical implant manufacturer will pay $2 million in fines and recoup nearly $600,000 in incentive-based compensation from four senior executives who allegedly manipulated the company’s financial statements, wrongdoing the Securities and Exchange Commission (SEC) said it identified through its earnings per share (EPS) initiative.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.